Morgan Stanley
MNPR icon

Morgan Stanley’s Monopar Therapeutics MNPR Stock Holding History

Morgan Stanley’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.66M Sell
17,919
-4,393
-20% -$272K ﹤0.01% 4947
2026
Q1 		$1.22M Sell
22,312
-4,655
-17% -$281K ﹤0.01% 5040
2025
Q4 		$1.76M Buy
26,967
+11,256
+72% +$920K ﹤0.01% 4898
2025
Q3 		$1.28M Buy
15,711
+7,779
+98% +$348K ﹤0.01% 5042
2025
Q2 		$284K Buy
7,932
+6,508
+457% +$236K ﹤0.01% 5712
2025
Q1 		$51.8K Sell
1,424
-2,377
-63% -$85.7K ﹤0.01% 6254
2024
Q4 		$83.6K Buy
+3,801
New +$63.8K ﹤0.01% 6127
2024
Q2 		– Sell
-160
Closed -$545 – 7925
2024
Q1 		$545 Hold
160
– – ﹤0.01% 7233
2023
Q4 		$272 Hold
160
– – ﹤0.01% 7274
2023
Q3 		$496 Sell
160
-640
-80% -$2.24K ﹤0.01% 7308
2023
Q2 		$3.42K Hold
800
– – ﹤0.01% 7068
2023
Q1 		$5.56K Hold
800
– – ﹤0.01% 7026
2022
Q4 		$9.48K Hold
800
– – ﹤0.01% 6957
2022
Q3 		$6K Hold
800
– – ﹤0.01% 7210
2022
Q2 		$9K Sell
800
-1
-0.1% -$11 ﹤0.01% 7247
2022
Q1 		$10K Buy
801
+1
+0.1% +$15 ﹤0.01% 7402
2021
Q4 		$13K Hold
800
– – ﹤0.01% 7381
2021
Q3 		$19K Hold
800
– – ﹤0.01% 7117
2021
Q2 		$24K Buy
800
+160
+25% +$4.58K ﹤0.01% 6944
2021
Q1 		$20K Hold
640
– – ﹤0.01% 6717
2020
Q4 		$20K Hold
640
– – ﹤0.01% 6435
2020
Q3 		$17K Hold
640
– – ﹤0.01% 6116
2020
Q2 		$24K Hold
640
– – ﹤0.01% 5961
2020
Q1 		$23K Sell
640
-1,486
-70% -$93K ﹤0.01% 5757
2019
Q4 		$177K Buy
+2,126
New +$222K ﹤0.01% 5460

Other funds holding MNPR

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Morgan Stanley's MNPR Position: Q2 2026 in Review

Morgan Stanley reduced its Monopar Therapeutics (MNPR) stake by 20% in Q2 2026, selling an estimated $272K and leaving 17,919 shares worth $1.66M. The position accounts for ﹤0.01% of the portfolio, ranked #4947.

Morgan Stanley first reported a position in MNPR in Q4 2019 and has held it in 25 quarters since. The position peaked at $1.76M in Q4 2025. 96 funds tracked by Wall St. Rank hold MNPR as of Q2 2026.

  • Morgan Stanley held 17,919 shares of Monopar Therapeutics worth $1.66M as of Q2 2026.
  • Morgan Stanley sold 4,393 Monopar Therapeutics shares in Q2 2026, an estimated $272K.
  • Monopar Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #4947 holding.
  • Morgan Stanley first reported a position in Monopar Therapeutics in Q4 2019 and has held it in 25 quarters since.
  • Morgan Stanley's Monopar Therapeutics position peaked at $1.76M in Q4 2025.
  • 96 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.